BioSpace News Archive

Genome Insight, a clinical laboratory, is proud to announce its accreditation by the College of American Pathologists (CAP) for its whole genome sequencing services.

Asimov announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.

Cyclo Therapeutics, Inc. today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo Therapeutics’ U.S. Patent Application No. 17/289,137 titled, “ Methods for Treating Alzheimer’s Disease.”

BIOTRONIK announced the milestone achievement of 100,000 implanted single lead implantable cardioverter-defibrillators equipped with DX Technology enabling direct atrial sensing for atrial fibrillation detection and monitoring.

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID® [Immune Globulin Infusion (Human) 10% solution] as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

The Future is Bright at FDAQRC, Achieving Unprecedented Success in 2023 Sets the Stage for a Stellar 2024!

Immunocore Holdings plc, announced its intention to offer, subject to market and other conditions, $300.0 million aggregate principal amount of convertible senior notes due 2030 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Phanes Therapeutics, Inc. announced that the U.S. Patent and Trademark Office has granted the registration of trademarks for its proprietary technology platforms PACbody®, SPECpair® and ATACCbody®.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to five new employees.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults.